Navigation Links
Bayer Appoints Bhavesh Ashar to Lead U.S. Oncology Business
Date:5/2/2017

WHIPPANY, N.J., May 2, 2017 /PRNewswire/ -- Bayer today announced the appointment of Bhavesh Ashar as senior vice president and head of Oncology for the company's Pharmaceuticals Division in the United States. Ashar will report to Carsten Brunn, Head of Bayer Pharmaceuticals for the Americas region.

"Bhavesh is a well-respected, results-driven leader with extensive industry knowledge and a proven track record of launching products and driving growth in oncology," said Brunn. "We are delighted to have Bhavesh join Bayer's U.S. Pharmaceuticals organization. I'm confident that he will help to advance our growing leadership in oncology and our ongoing commitment to meeting the needs of people living with cancer."

Previously, Ashar served as vice president and general manager of U.S. Oncology at Sanofi and was responsible for managing a diverse portfolio comprising solid tumor, hematology and transplant products. Ashar was with Sanofi for more than 14 years and held positions of increasing responsibility in sales and marketing, with a strong focus on specialty markets. Prior to joining Sanofi, Ashar served as an engagement manager with McKinsey & Company.

Bayer's diverse oncology portfolio and pipeline is helping to address some of the most difficult to treat cancers in areas of high unmet need. The oncology franchise includes three marketed products and several other compounds in various stages of clinical development.

"Oncology is a critical growth driver for Bayer and I am excited to help the company realize the full potential of its diverse cancer portfolio," said Ashar.

Ashar holds a Bachelor of Science degree in Mathematics from Imperial College in London and an MBA from the University of Chicago Booth School of Business.

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.

© 2017 Bayer

Forward-Looking Statement
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Intended for U.S. Media Only

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bayer-appoints-bhavesh-ashar-to-lead-us-oncology-business-300449550.html


'/>"/>
SOURCE Bayer
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
2. Statement: Bayer Mourns Passing of Senator Frank Lautenberg
3. FDA Advisory Committee Unanimously Recommends Approval Of Bayers Riociguat In Two Pulmonary Hypertension Indications
4. Among the Novel Oral Anticoagulants, Bayer/Janssens Xarelto is Positioned To Be the Sales-Leading Therapy for Venous Thromboembolism (VTE)
5. Bayer and the Broad Institute Join Forces to Develop Novel Treatment Options in Cancer Therapy
6. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
7. Bayer HealthCare Awards Veterinary Students $72,500 in Scholarship Funds for Communications Excellence
8. Bayers Third Annual Virtual Walk for Hemophilia Raises Funds, Brings Together the Hemophilia Community
9. Bayer HealthCare Announces Collaboration with the University of Texas MD Anderson Cancer Center
10. Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration
11. Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... LAWRENCE, Mass. and SAN DIEGO ... of Obstetricians and Gynecologists (ACOG) 2017 Annual Clinical and ... of single-use, self-contained, illuminating medical devices, today announced the ... size of its OfficeSPEC and ER-SPEC ... large, the addition of extra-small and extra-large sizes makes ...
(Date:5/3/2017)... , May 3, 2017  Kalorama Information notes ... nine percent next year and this is projected ... hematopoietic stem cell (HSCT) or bone marrow transplants ... technologies are well-suited for this task. This according ... publisher Kalorama Information. The various PCR-based methodologies, Sanger ...
(Date:5/2/2017)...  CIVCO Radiotherapy, the leading provider of high ... Nat Geissel has been named president. ... has served as vice president of marketing and ... manager, and most recently, executive vice president and ... of what CIVCO Radiotherapy and its predecessors have ...
Breaking Medicine Technology:
(Date:5/21/2017)... ... 21, 2017 , ... Following the tragic and widely publicized death of Rory ... require that hospitals follow a protocol to quickly identify and treat the condition. ... such steps would have saved Rory or anyone else’s life. , Now, five ...
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... In a ... PlushBeds , a luxury online mattress company that specializes in natural and organic ... nation’s leading grassroots autism organization) for every unique share their recent viral Facebook ...
(Date:5/19/2017)... Jupiter, FL (PRWEB) , ... May 19, 2017 ... ... will feature RawTrition’s BioEnergy in an upcoming episode of Innovations with Ed Begley, ... New Jersey, RawTrition is the distributor of a clean, organic dietary supplement made ...
(Date:5/19/2017)... ... May 19, 2017 , ... Springfield, Vermont-based law firm of ... " Ten Good Reasons To Hire An Experienced Personal Injury Attorney, " the article ... accident or injury. As the article says. if someone is injured due to ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Miller Agency, a Jacksonville ... and business owners in the region, is embarking on a cooperative charity event ... families. , Multiple sclerosis (MS) is a demyelinating disease that affects the insulation ...
Breaking Medicine News(10 mins):